Iambic Therapeutics

Iambic reports early IAM1363 Phase 1/1b anti-tumor activity: 28 percent partial responses among 18 participants with measurable systemic disease at the specified dose threshold.

Iambic has advanced AI-designed therapeutics into clinical and IND-enabling programs, including IAM1363 in Phase 1/1b, but commercial deployment remains narrower than general AI platforms.

Iambic has advanced AI-designed therapeutics into clinical and IND-enabling programs, including IAM1363 in Phase 1/1b, but commercial deployment remains narrower than general AI platforms.

Iambic develops multimodal transformer and protein-ligand structure prediction systems, including Enchant and NeuralPLexer, for end-to-end drug discovery.

Iambic develops multimodal transformer and protein-ligand structure prediction systems, including Enchant and NeuralPLexer, for end-to-end drug discovery.

Iambic’s molecular-superintelligence platform integrates Enchant multimodal property prediction, NeuralPLexer flow-matching biomolecular structure prediction and automated chemistry/biology experimentation in a continuous design-make-test loop that learns from newly generated laboratory data.

Iambic announced raising more than $100 million in an oversubscribed financing round in 2025, with support from new and existing investors. This capital-backing disclosure is independent of its generic AI/laboratory capabilities and pharmaceutical collaborations; no current liquidity or therapeutic efficacy conclusion is inferred.

Iambic combines AI research, high-throughput experimentation and clinical drug-development execution, including collaborations with major pharmaceutical companies.

Iambic combines AI research, high-throughput experimentation and clinical drug-development execution, including collaborations with major pharmaceutical companies.

Iambic's NeuralPLexer2 report details hardware- and memory-optimized geometric attention, an atomic-context pipeline for filtering artifact ligands from 134,000 PDB structures, and model/compute scaling analysis using validation loss.

ML and multimodal modeling skills transfer broadly, while medicinal chemistry, biology and clinical-development specialization limit full portability.

ML and multimodal modeling skills transfer broadly, while medicinal chemistry, biology and clinical-development specialization limit full portability.